For the first time in twenty years, Australians living with rare IDH-mutant brain tumours have a new therapeutic option — not merely a new drug, but access to one, as vorasidenib joins the Pharmaceutical Benefits Scheme this week. The listing transforms a $28,000 monthly cost into $25, placing within reach a treatment that can slow or halt the progression of cancers that quietly dismantle the lives of people in the prime of their working and family years. In a disease where time is the most precious currency, this decision by Australia's health authorities is an act of collective care — a reco
First brain cancer treatment in 20 years added to PBS, slashing costs for patients
Approximately 3,230 Australians live with these incurable brain tumours, experiencing seizures, cognitive changes, physical disability, and loss of independence over many years.